Marksans Pharma Limited (MARKSANS.BO)
INR 223.6
(2.1%)
INR 223.6
(2.1%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.13 Billion INR | 17.8% |
| 2022 | 2.66 Billion INR | 44.29% |
| 2021 | 1.84 Billion INR | -22.62% |
| 2020 | 2.38 Billion INR | 97.54% |
| 2019 | 1.2 Billion INR | 50.12% |
| 2018 | 804.37 Million INR | 124.68% |
| 2017 | 358 Million INR | 305.06% |
| 2016 | 88.38 Million INR | -88.74% |
| 2015 | 785.11 Million INR | -28.23% |
| 2014 | 1.09 Billion INR | 52.13% |
| 2013 | 719.07 Million INR | 56.72% |
| 2012 | 458.84 Million INR | 125.66% |
| 2011 | -1.78 Billion INR | -12793.24% |
| 2010 | -13.87 Million INR | 86.19% |
| 2009 | -100.43 Million INR | -20.2% |
| 2008 | -83.55 Million INR | -153.16% |
| 2007 | 157.18 Million INR | 134.85% |
| 2006 | 66.93 Million INR | -70.76% |
| 2005 | 228.91 Million INR | 11.35% |
| 2004 | 205.58 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 887.52 Million INR | 13.36% |
| 2023 Q4 | 782.89 Million INR | -5.94% |
| 2023 Q2 | 835.18 Million INR | 21.64% |
| 2023 Q3 | 832.35 Million INR | -0.34% |
| 2023 FY | 3.13 Billion INR | 17.8% |
| 2023 Q1 | 686.58 Million INR | -16.2% |
| 2022 Q4 | 819.32 Million INR | 29.21% |
| 2022 Q3 | 634.08 Million INR | 3.52% |
| 2022 FY | 2.66 Billion INR | 44.29% |
| 2022 Q1 | 597.16 Million INR | 101.39% |
| 2022 Q2 | 612.53 Million INR | 2.57% |
| 2021 Q4 | 296.52 Million INR | -39.63% |
| 2021 Q2 | 454.91 Million INR | -26.44% |
| 2021 Q3 | 491.21 Million INR | 7.98% |
| 2021 FY | 1.84 Billion INR | -22.62% |
| 2021 Q1 | 618.46 Million INR | -22.21% |
| 2020 FY | 2.38 Billion INR | 97.54% |
| 2020 Q1 | 493.65 Million INR | 15.49% |
| 2020 Q2 | 507.34 Million INR | 2.77% |
| 2020 Q3 | 589.4 Million INR | 16.17% |
| 2020 Q4 | 794.99 Million INR | 34.88% |
| 2019 FY | 1.2 Billion INR | 50.12% |
| 2019 Q1 | 224.82 Million INR | 128.19% |
| 2019 Q2 | 259.7 Million INR | 15.51% |
| 2019 Q3 | 295.6 Million INR | 13.82% |
| 2019 Q4 | 427.42 Million INR | 44.6% |
| 2018 Q2 | 205.73 Million INR | -17.3% |
| 2018 Q4 | 98.52 Million INR | -60.8% |
| 2018 FY | 804.37 Million INR | 124.68% |
| 2018 Q1 | 248.78 Million INR | 461.23% |
| 2018 Q3 | 251.34 Million INR | 22.17% |
| 2017 Q2 | 94.23 Million INR | -34.64% |
| 2017 FY | 358 Million INR | 305.06% |
| 2017 Q4 | -68.87 Million INR | -139.46% |
| 2017 Q3 | 174.55 Million INR | 85.24% |
| 2017 Q1 | 144.18 Million INR | 548.01% |
| 2016 Q1 | 44.31 Million INR | 176.94% |
| 2016 FY | 88.38 Million INR | -88.74% |
| 2016 Q3 | 99.57 Million INR | 1364.26% |
| 2016 Q4 | -32.18 Million INR | -132.32% |
| 2016 Q2 | 6.8 Million INR | -84.65% |
| 2015 FY | 785.11 Million INR | -28.23% |
| 2015 Q2 | 348.71 Million INR | 10.81% |
| 2015 Q1 | 314.69 Million INR | 25.64% |
| 2015 Q3 | 179.34 Million INR | -48.57% |
| 2015 Q4 | -57.59 Million INR | -132.11% |
| 2014 Q4 | 250.47 Million INR | -9.63% |
| 2014 Q2 | 311.63 Million INR | 22.36% |
| 2014 FY | 1.09 Billion INR | 52.13% |
| 2014 Q1 | 254.69 Million INR | 139.6% |
| 2014 Q3 | 277.17 Million INR | -11.06% |
| 2013 Q2 | 200.11 Million INR | 6.54% |
| 2013 FY | 719.07 Million INR | 56.72% |
| 2013 Q4 | 106.29 Million INR | -52.72% |
| 2013 Q3 | 224.83 Million INR | 12.35% |
| 2013 Q1 | 187.83 Million INR | -53.88% |
| 2012 Q3 | 82.11 Million INR | -41.45% |
| 2012 Q2 | 140.24 Million INR | 182.13% |
| 2012 FY | 458.84 Million INR | 125.66% |
| 2012 Q1 | -170.76 Million INR | 0.0% |
| 2012 Q4 | 407.24 Million INR | 395.96% |
| 2011 FY | -1.78 Billion INR | -12793.24% |
| 2010 FY | -13.87 Million INR | 86.19% |
| 2009 FY | -100.43 Million INR | -20.2% |
| 2008 FY | -83.55 Million INR | -153.16% |
| 2007 FY | 157.18 Million INR | 134.85% |
| 2006 FY | 66.93 Million INR | -70.76% |
| 2005 FY | 228.91 Million INR | 11.35% |
| 2004 FY | 205.58 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott India Limited | 12.01 Billion INR | 73.885% |
| Cipla Limited | 41.21 Billion INR | 92.389% |
| Gland Pharma Limited | 7.72 Billion INR | 59.389% |
| GlaxoSmithKline Pharmaceuticals Limited | 5.89 Billion INR | 46.827% |
| Kopran Limited | 509.56 Million INR | -515.627% |
| NGL Fine-Chem Limited | 413.16 Million INR | -659.257% |
| Pfizer Limited | 5.51 Billion INR | 43.101% |
| Sanofi India Limited | 6.02 Billion INR | 47.968% |
| SMS Pharmaceuticals Limited | 498.26 Million INR | -529.591% |